Compare Stocks: OPT, STOK, BHVN, and ZBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$15.41 -4.4%	$14.82	$7.48 ▼ $18.57	$2.33B	1.26	2.90 million shs	2.89 million shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
STOK Stoke Therapeutics	$31.62 -3.0%	$31.22	$18.80 ▼ $40.22	$2.04B	1.2	987,152 shs	754,095 shs
ZBIO Zenas BioPharma	$31.27 -4.1%	$29.62	$13.50 ▼ $44.60	$2.04B	-1.03	715,661 shs	439,130 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	0.00%	+10.78%	+11.42%	+39.90%	-1.27%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
STOK Stoke Therapeutics	0.00%	-2.07%	+5.26%	+2.30%	+63.83%
ZBIO Zenas BioPharma	0.00%	-3.16%	-3.10%	+69.95%	+87.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$15.41 -4.4%	$14.82	$7.48 ▼ $18.57	$2.33B	1.26	2.90 million shs	2.89 million shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
STOK Stoke Therapeutics	$31.62 -3.0%	$31.22	$18.80 ▼ $40.22	$2.04B	1.2	987,152 shs	754,095 shs
ZBIO Zenas BioPharma	$31.27 -4.1%	$29.62	$13.50 ▼ $44.60	$2.04B	-1.03	715,661 shs	439,130 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	0.00%	+10.78%	+11.42%	+39.90%	-1.27%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
STOK Stoke Therapeutics	0.00%	-2.07%	+5.26%	+2.30%	+63.83%
ZBIO Zenas BioPharma	0.00%	-3.16%	-3.10%	+69.95%	+87.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.65	Moderate Buy	$18.94	22.89% Upside
OPT Opthea	1.00	Sell	N/A	N/A
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	39.94% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$45.71	46.19% Upside

Current Analyst Ratings Breakdown

Latest OPT, STOK, BHVN, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/21/2026	STOK Stoke Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$40.00
8/14/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $32.00
8/14/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
8/14/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00
8/11/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
OPT Opthea	$25K	20,993.46	N/A	N/A	($1.31) per share	-2.60
STOK Stoke Therapeutics	$184.42M	11.06	N/A	N/A	$6.17 per share	5.12
ZBIO Zenas BioPharma	$10M	203.82	N/A	N/A	$4.51 per share	6.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
OPT Opthea	-$162.79M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	11/12/2026 (Estimated)

Latest OPT, STOK, BHVN, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
OPT Opthea	N/A	0.22	0.22
STOK Stoke Therapeutics	N/A	7.69	7.69
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
OPT Opthea	55.95%
STOK Stoke Therapeutics	N/A
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
OPT Opthea	3.20%
STOK Stoke Therapeutics	9.60%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
OPT Opthea	8	153.91 million	165.53 million	Not Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable
ZBIO Zenas BioPharma	N/A	65.18 million	50.84 million	N/A

OPT, STOK, BHVN, and ZBIO Headlines

Recent News About These Companies

J. Goldman & Co LP Acquires New Position in Zenas BioPharma, Inc. $ZBIO

August 26, 2026 | marketbeat.com

Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO

August 26, 2026 | marketbeat.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 23, 2026 | americanbankingnews.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Brokerages

August 23, 2026 | marketbeat.com

HC Wainwright Forecasts Higher Earnings for Zenas BioPharma

August 20, 2026 | americanbankingnews.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2026 | globenewswire.com

HC Wainwright Predicts Higher Earnings for Zenas BioPharma

August 18, 2026 | marketbeat.com

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO

August 15, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

August 14, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

August 14, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 13, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

August 13, 2026 | marketbeat.com

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

July 14, 2026 | seekingalpha.com

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

July 11, 2026 | finance.yahoo.com

Zenas BioPharma Inc ZBIO

June 27, 2026 | morningstar.comM

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

June 24, 2026 | theglobeandmail.com

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

June 21, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, STOK, BHVN, and ZBIO Company Descriptions

Biohaven NYSE:BHVN

$15.41 -0.71 (-4.40%)

As of 08/28/2026 03:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Opthea NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Stoke Therapeutics NASDAQ:STOK

$31.62 -0.97 (-2.98%)

As of 08/28/2026 04:00 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$31.27 -1.35 (-4.14%)

As of 08/28/2026 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, STOK, BHVN, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, STOK, BHVN, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, STOK, BHVN, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, STOK, BHVN, and ZBIO Company Descriptions

Biohaven NYSE:BHVN

Opthea NASDAQ:OPT

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, STOK, BHVN, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, STOK, BHVN, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, STOK, BHVN, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, STOK, BHVN, and ZBIO Company Descriptions

Biohaven NYSE:BHVN

Opthea NASDAQ:OPT

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools